Sara Ek

Prof. Sara Ek

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2017 in Blood
Verified
Journal Article
Closed access
PDF file
CEChristian Winther Eskelund
Christian Winther Eskelund
CDChristina Dahl
Christina Dahl
JHJakob W. Hansen
Jakob W. Hansen
MWMaj Westman
Maj Westman
AKArne Kolstad
Arne Kolstad
KGKirsten Grønbæk
Kirsten Grønbæk
Despite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains incurable and we are still unable to identify patients who will not benefit from the current standard-of-care. Here, we explore the prognostic value of recurrent genetic aberrations in diagnostic bone marrow (BM) specimens from 183 younger MCL patients from the Nordic MCL2 and MCL3 trials, which represent current standard-of-care regimens. In the univariate model, mutations of TP53 (11%) and NOTCH1 (4%), and deletions of TP53 (16%) and CDKN2A (20%) were significantly associated with inferior outcomes (together with MIPI, MIPI-c, Blastoid morphology and Ki67>30%); however, in multivariate analyses only TP53 mutations (HR=6.2, p<0.0001) retained prognostic impact for overall survival (OS), while TP53 mutations (HR=6.9, p<0.0001) and MIPI-c high-risk (HR=2.6, p=0.003) had independent prognostic impact on time to relapse. TP53-mutated cases had a dismal outcome with a median OS of 1.8 years and 50% relapsed at 1.0 years (compared to not reached (NR) and 12.7 years, respectively, for TP53-unmutated cases, p30%, blastoid morphology, MIPI high-risk and inferior responses to both induction- and high-dose chemotherapy. In conclusion, we show that TP53 mutations identify a phenotypically distinct and highly aggressive form of MCL with poor or no response to regimens including cytarabine, rituximab and autologous stem-cell transplant (ASCT). We suggest that MCL patients should be stratified according to TP53 status, and that patients with TP53 mutations should be considered for experimental frontline trials exploring novel agents. Key points The intensified standard-of-care regimens for younger MCL patients do not overcome the deleterious effects of TP53 mutations. MCLs with TP53 mutations should be considered for alternative frontline treatment.

15 January 2008 in Blood
Verified
Journal Article
Open access
PDF file
SESara Ek
Sara Ek
MDMichael Dictor
Michael Dictor
MJMats Jerkeman
Mats Jerkeman
KJKarin Jirström
Karin Jirström
CBCarl A. K. Borrebaeck
Carl A. K. Borrebaeck
Mantle cell lymphoma (MCL) is defined pathologically by the detection of CD20, CD5, and most importantly cyclin D1 (CCND1). Its distinction from other lymphomas is important for prognosis and appropriate therapy, but occasional cases may fail to express CCND1 and morphologic simulators may express CD20 and CD5 but not CD23. In this study, we show that the transcription factor Sox11 is specifically expressed in the nucleus of MCL compared with other lymphomas and benign lymphoid tissue. Although the role of Sox11 presently is not known in lymphocyte ontogeny, it is normally expressed in the developing central nervous system in the embryo and shows sequence homology with Sox4, a transcription factor crucial for B lymphopoiesis. Sox11 mRNA is increased in gliomas compared with healthy brain tissue, suggesting a role in malignant transformation and/or cell survival. Our novel finding of specific overexpression of Sox11 mRNA and nuclear protein in both cyclin D1–positive and – negative MCL may be useful for the diagnosis of MCL as a complement to cyclin D1 and also suggests a functional role for Sox11 in MCL.

30 October 2009 in Haematologica
Verified
Journal Article
Closed access
MDM. Dictor
M. Dictor
SESara Ek
Sara Ek
MSM. Sundberg
M. Sundberg
JWJ. Warenholt
J. Warenholt
CGC. Gyorgy
C. Gyorgy
CBC. Borrebaeck
C. Borrebaeck
We surveyed lymphomas to determine the range of expression of the mantle cell lymphoma-associated SOX11 transcription factor and its relation to cyclin D1. On hundred and seventy-two specimens were immunostained for the SOX11 N and C termini. Cyclin D1 was detected by immunohistochemistry and quantitative reverse transcriptase polymerase chain reaction; in situ hybridization for t(11;14) was applied when needed. Nuclear SOX11 was strongly expressed in most B and T-lymphoblastic leukemia/lymphomas and half of childhood Burkitt's lymphomas, but only weakly expressed in some hairy cell leukemias. Chronic lymphocytic leukemia/lymphoma, marginal zone, follicular and diffuse large B-cell lymphomas were negative for SOX11, as were all cases of intermediate Burkitt's lymphomas/diffuse large B-cell lymphoma, myeloma, Hodgkin's lymphomas and mature T-cell and NK/T-cell lymphomas. In addition to mantle cell lymphoma, SOX11 is strongly expressed only in lymphoblastic malignancies and Burkitt's lymphomas. Its expression is independent of cyclin D1 (except for weak expression in hairy cell leukemias) and unlikely to be due to translocations in lymphoid neoplasia.

29 March 2014 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
LNLena Nordström
Lena Nordström
SSSandra Sernbo
Sandra Sernbo
PEPatrik Eden
Patrik Eden
KGKirsten Grønbæk
Kirsten Grønbæk
AKArne Kolstad
Arne Kolstad
SESara Ek
Sara Ek
Summary: Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the NordicMCL2/3 protocols. In 2008, aMCLinternational prognostic index (MIPI) was created to enable stratification of the clinical diverseMCLpatients into three risk groups. So far, use of theMIPIin clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment‐related morbidity, additional parameters need to be evaluated to enable risk‐adapted treatment selection. We have investigated the individual prognostic role of theMIPIand molecular markers includingSOX11,TP53 (p53),MKI67 (Ki‐67) and CCND1 (cyclin D1). Furthermore, we explored the possibility of creating an improved prognostic tool by combining theMIPIwith information on molecular markers.SOX11 was shown to significantly add prognostic information to theMIPI, but in multivariate analysisTP53 was the only significant independent molecular marker. Based on these findings, we propose thatTP53 andSOX11 should routinely be assessed and that a combinedTP53/MIPIscore may be used to guide treatment decisions.

15 August 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ACAnders Carlsson
Anders Carlsson
CWChrister Wingren
Christer Wingren
MKMalin Kristensson
Malin Kristensson
CRCarsten Rose
Carsten Rose
MFMårten Fernö
Mårten Fernö
CBCarl Borrebaeck
Carl Borrebaeck
The risk of distant recurrence in breast cancer patients is difficult to assess with current clinical and histopathological parameters, and no validated serum biomarkers currently exist. Using a recently developed recombinant antibody microarray platform containing 135 antibodies against 65 mainly immunoregulatory proteins, we screened 240 sera from 64 patients with primary breast cancer. This unique longitudinal sample material was collected from each patient between 0 and 36 mo after the primary operation. The velocity for each serum protein was determined by comparing the samples collected at the primary operation and then 3–6 mo later. A 21-protein signature was identified, using leave-one-out cross-validation together with a backward elimination strategy in a training cohort. This signature was tested and evaluated subsequently in an independent test cohort (prevalidation). The risk of developing distant recurrence after primary operation could be assessed for each patient, using her molecular portraits. The results from this prevalidation study showed that patients could be classified into high- versus low-risk groups for developing metastatic breast cancer with a receiver operating characteristic area under the curve of 0.85. This risk assessment was not dependent on the type of adjuvant therapy received by the patients. Even more importantly, we demonstrated that this protein signature provided an added value compared with conventional clinical parameters. Consequently, we present here a candidate serum biomarker signature able to classify patients with primary breast cancer according to their risk of developing distant recurrence, with an accuracy outperforming current procedures.

1 May 2009 in European Journal of Cancer
Verified
Journal Article
Closed access
DBDonal J. Brennan
Donal J. Brennan
SESara Ek
Sara Ek
EDEmma Doyle
Emma Doyle
TDThomas Drew
Thomas Drew
MFMichael Foley
Michael Foley
CBCarl A.K. Borrebaeck
Carl A.K. Borrebaeck